

# ZINNAT

## Cefuroxime axetil

### QUALITATIVE AND QUANTITATIVE COMPOSITION

*ZINNAT* tablets containing either 125, 250 or 500 mg of cefuroxime (as cefuroxime axetil).

### CLINICAL INFORMATION

#### Indications

*ZINNAT* is an oral prodrug of the bactericidal cephalosporin antibiotic cefuroxime, which is resistant to most  $\beta$ (beta)-lactamases and is active against a wide range of Gram-positive and Gram-negative organisms.

It is indicated for the treatment of infections caused by susceptible bacteria. Susceptibility to *ZINNAT* will vary with geography and time, and it should be used in accordance with local official antibiotic prescribing guidelines and local susceptibility data (*See Pharmacological properties, Pharmacodynamics*).

Indications include:

- upper respiratory tract infections for example, ear, nose and throat infections, such as otitis media, sinusitis, tonsillitis and pharyngitis
- lower respiratory tract infections for example, pneumonia and acute exacerbations of chronic obstructive pulmonary disease
- genito-urinary tract infections for example, pyelonephritis, cystitis and urethritis
- skin and soft tissue infections for example, furunculosis, pyoderma and impetigo
- gonorrhoea, acute uncomplicated gonococcal urethritis and cervicitis
- treatment of early Lyme disease and subsequent prevention of late Lyme disease.

Cefuroxime is also available as the sodium salt (*ZINACEF*) for parenteral administration. This permits the use of sequential therapy with the same antibiotic, when a change from parenteral to oral therapy is clinically indicated.

Where appropriate *ZINNAT* is effective when used following initial parenteral *ZINACEF* (cefuroxime sodium) in the treatment of pneumonia and acute exacerbations of chronic obstructive pulmonary disease.

## Dosage and Administration

Pharmaceutical Form: Coated tablet.

The usual course of therapy is seven days (range 5 to 10 days). The dose of cefuroxime that is selected to treat an individual infection should take into account:

- The expected pathogens and their likely susceptibility to cefuroxime axetil
- The severity and the site of the infection
- The age, weight and renal function of the patient; as shown below.

The duration of therapy should be determined by the type of infection and the response of the patient, and should generally not be longer than recommended.

*ZINNAT* should be taken after food for optimum absorption.

- **Adults and Children weighing more than 40 kg**

<b>Indication</b>	<b>Dosage</b>
Acute tonsillitis and pharyngitis	250 mg twice daily
Acute otitis media	500 mg twice daily
Acute bacterial sinusitis	500 mg twice daily
Community acquired pneumonia	500 mg twice daily
Acute exacerbations of chronic obstructive pulmonary disease	500 mg twice daily
Urinary tract infections	250 mg – 500 mg twice daily
Uncomplicated gonorrhoea	single dose of 1 g
Skin and soft tissue infections	250 mg – 500 mg twice daily
Lyme disease in adults and children over the age of 12 years	500 mg twice daily for 14 days (range of 10-21 days)

### Sequential therapy

Duration of both parenteral and oral therapy is determined by the severity of the infection and the clinical status of the patient.

### **Pneumonia**

1.5 g *ZINACEF* three times a day or twice a day (intravenous (i.v.) or intramuscular (i.m)) for 48 to 72 hours, followed by *ZINNAT* (cefuroxime axetil) oral therapy 500 mg twice a day for 7 to 10 days.

### **Acute exacerbations of chronic obstructive pulmonary disease**

750 mg *ZINACEF* three times a day or twice a day (i.v. or i.m.) for 48 to 72 hours, followed by *ZINNAT* (cefuroxime axetil) oral therapy 500 mg twice a day for 5 to 10 days.

- Children weighing between 20-40 kg

*ZINNAT* tablets should not be crushed or split and are therefore unsuitable for treatment of patients, such as younger children, who cannot swallow whole tablets. Therefore, cefuroxime axetil suspension is recommended for patients who cannot swallow whole tablets.

<b>Indication</b>	<b>Dosage</b>
Acute tonsillitis and pharyngitis	250 mg twice daily
Acute otitis media	250 mg twice daily to 500 mg twice daily
Acute bacterial sinusitis	
Community acquired pneumonia	
Urinary tract infections	
Skin and soft tissue infections	
Lyme Disease in children under the age of 12 years	250 mg twice daily to 500 mg twice daily for 14 days (range of 10 to 21 days).

- **Renal impairment**

Cefuroxime is primarily excreted by the kidneys. In patients with markedly impaired renal function it is recommended that the dosage of cefuroxime be reduced to compensate for its slower excretion (see the table below).

<b>Creatinine Clearance</b>	<b>T<sub>1/2</sub> (hours)</b>	<b>Recommended Dosage</b>
≥30 ml/min	1.4 - 2.4	No dose adjustment necessary standard dose of 125 mg to 500 mg given twice daily
10-29 ml/min	4.6	Standard individual dose given every 24 hours
<10 ml/min	16.8	Standard individual dose given every 48 hours
During haemodialysis	2 – 4	A single additional standard individual dose should be given at the end of each dialysis

## **Contraindications**

Patients with known hypersensitivity to cephalosporin antibiotics.

## **Warnings and Precautions**

Special care is indicated in patients who have experienced an allergic reaction to penicillins, or other beta-lactams.

As with other antibiotics, use of *ZINNAT* may result in the overgrowth of *Candida*. Prolonged use may also result in the overgrowth of other non-susceptible organisms (e.g. enterococci and *Clostridium difficile*), which may require interruption of treatment.

Pseudomembranous colitis has been reported with the use of antibiotics, and may range in severity from mild to life-threatening. Therefore, it is important to consider its diagnosis in patients who develop diarrhoea during or after antibiotic use. If prolonged or significant diarrhoea occurs or the patient experiences abdominal cramps, treatment should be discontinued immediately and the patient investigated further.

The Jarisch-Herxheimer reaction has been seen following *ZINNAT* treatment of Lyme disease. It results directly from the bactericidal activity of *ZINNAT* on the causative organism of Lyme disease, the spirochaete *Borrelia burgdorferi*. Patients should be reassured that this is a common and usually self-limiting consequence of antibiotic treatment of Lyme disease.

With a sequential therapy regime the timing of change to oral therapy is determined by severity of the infection, clinical status of the patient and susceptibility of the pathogens involved. If there is no clinical improvement within 72 hours, then the parenteral course of treatment must be continued.

Please refer to the relevant prescribing information for cefuroxime sodium before initiating sequential therapy.

## **Interactions**

Drugs which reduce gastric acidity may result in a lower bioavailability of *ZINNAT* compared with that of the fasting state and tend to cancel the effect of enhanced post-prandial absorption.

In common with other antibiotics, *ZINNAT* may affect the gut flora, leading to lower oestrogen reabsorption and reduced efficacy of combined oral contraceptives.

As a false negative result may occur in the ferricyanide test, it is recommended that either the glucose oxidase or hexokinase methods are used to determine blood/plasma glucose levels in patients receiving *ZINNAT*. This antibiotic does not interfere in the alkaline picrate assay for creatinine.

## **Pregnancy and Lactation**

### **Pregnancy**

There is no experimental evidence of embryopathic or teratogenic effects attributable to *ZINNAT* but, as with all drugs, it should be administered with caution during the early months of pregnancy.

### **Lactation**

Cefuroxime is excreted in human milk, and consequently caution should be exercised when *ZINNAT* is administered to a nursing mother.

## **Effects on Ability to Drive and Use Machines**

As this medicine may cause dizziness, patients should be warned to be cautious when driving or operating machinery.

## **Adverse Reactions**

Adverse drug reactions to *ZINNAT* are generally mild and transient in nature.

The frequency categories assigned to the adverse reactions below are estimates, as for most reactions suitable data (for example from placebo-controlled studies) for calculating incidence were not available. In addition the incidence of adverse reactions associated with *ZINNAT* may vary according to the indication.

Data from large clinical studies were used to determine the frequency of very common to rare undesirable effects. The frequencies assigned to all other undesirable effects (i.e. those occurring at  $<1/1000$ ) were mainly determined using post-marketing data and refer to a reporting rate rather than true frequency. Placebo-controlled trial data were not available. Where incidences have been calculated from clinical trial data, these were based on drug-related (investigator assessed) data.

The following convention has been used for the classification of frequency:

very common  $\geq 1/10$   
common  $\geq 1/100$  to  $<1/10$   
uncommon  $\geq 1/1000$  to  $<1/100$   
rare  $\geq 1/10,000$  to  $<1/1000$   
very rare  $<1/10,000$

### **Infections and infestations**

Common: Overgrowth of *Candida*

### **Blood and lymphatic system disorders**

Common: Eosinophilia

Uncommon: Positive Coombs' test, thrombocytopenia, leukopenia (sometimes profound)

Very rare: Haemolytic anaemia

Cephalosporins as a class tend to be absorbed onto the surface of red cells membranes and react with antibodies directed against the drug to produce a positive Coombs' test (which can interfere with cross-matching of blood) and very rarely haemolytic anaemia.

### **Immune system disorders**

Hypersensitivity reactions including

Uncommon: Skin rashes

Rare: Urticaria, pruritus

Very rare: Drug fever, serum sickness, anaphylaxis

### **Nervous system disorders**

Common: Headache, dizziness

### **Gastrointestinal disorders**

Common: Gastrointestinal disturbances including diarrhoea, nausea, abdominal pain

Uncommon: Vomiting

Rare: Pseudomembranous colitis (*See Warnings and Precautions*)

## Hepatobiliary disorders

- Common: Transient increases of hepatic enzyme levels, [ALT (SGPT), AST (SGOT), LDH]  
Very rare: Jaundice (predominantly cholestatic), hepatitis

## Skin and subcutaneous tissue disorders

- Very rare: Erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis (exanthematic necrolysis)

See also Immune system disorders.

## Overdose

## Signs and symptoms

Overdosage of cephalosporins can cause cerebral irritation leading to convulsions.

## Treatment

Serum levels of cefuroxime can be reduced by haemodialysis and peritoneal dialysis.

## PHARMACOLOGICAL PROPERTIES

### Pharmacodynamics

The prevalence of acquired resistance is geographically and time dependent and for select species may be very high. Local information on resistance is desirable, particularly when treating severe infections.

#### ***In vitro* susceptibility of micro-organisms to Cefuroxime**

Where clinical efficacy of cefuroxime axetil has been demonstrated in clinical trials this is indicated with an asterisk (\*).

#### **Commonly Susceptible Species**

##### Gram-Positive Aerobes:

*Staphylococcus aureus* (methicillin susceptible)\*

*Coagulase negative staphylococcus* (methicillin susceptible)

*Streptococcus pyogenes*\*

Beta-hemolytic streptococci

##### Gram-Negative Aerobes:

*Haemophilus influenzae*\* including ampicillin resistant strains

*Haemophilus parainfluenzae*\*

<p><i>Moraxella catarrhalis</i>*</p> <p><i>Neisseria gonorrhoea</i>* including penicillinase and non-penicillinase producing strains</p>
<p><u>Gram-Positive Anaerobes:</u></p> <p><i>Peptostreptococcus</i> spp.</p> <p><i>Propionibacterium</i> spp.</p>
<p><u>Spirochetes:</u></p> <p><i>Borrelia burgdorferi</i>*</p>
<p><b>Organisms for which acquired resistance may be a problem</b></p>
<p><u>Gram-Positive Aerobes:</u></p> <p><i>Streptococcus pneumoniae</i>*</p>
<p><u>Gram-Negative Aerobes:</u></p> <p><i>Citrobacter</i> spp. not including <i>C. freundii</i></p> <p><i>Enterobacter</i> spp. not including <i>E. aerogenes</i> and <i>E. cloacae</i></p> <p><i>Escherichia coli</i>*</p> <p><i>Klebsiella</i> spp. including <i>Klebsiella pneumoniae</i>*</p> <p><i>Proteus mirabilis</i></p> <p><i>Proteus</i> spp. not including <i>P. penneri</i> and <i>P. vulgaris</i></p> <p><i>Providencia</i> spp.</p>
<p><u>Gram-Positive Anaerobes:</u></p> <p><i>Clostridium</i> spp.</p>
<p><u>Gram-Negative Anaerobes:</u></p> <p><i>Bacteroides</i> spp. not including <i>B. fragilis</i></p> <p><i>Fusobacterium</i> spp.</p>
<p><b>Inherently resistant organisms</b></p>
<p><u>Gram-Positive Aerobes:</u></p> <p><i>Enterococcus</i> spp. including <i>E. faecalis</i> and <i>E. faecium</i></p> <p><i>Listeria monocytogenes</i></p>
<p><u>Gram-Negative Aerobes:</u></p> <p><i>Acinetobacter</i> spp.</p> <p><i>Burkholderia cepacia</i></p>



<p><i>Campylobacter</i> spp.</p> <p><i>Citrobacter freundii</i></p> <p><i>Enterobacter aerogenes</i></p> <p><i>Enterobacter cloacae</i></p> <p><i>Morganella morganii</i></p> <p><i>Proteus penneri</i></p> <p><i>Proteus vulgaris</i></p> <p><i>Pseudomonas</i> spp. including <i>Pseudomonas aeruginosa</i></p> <p><i>Serratia</i> spp.</p> <p><i>Stenotrophomonas maltophilia</i></p>
<p><u>Gram-Positive Anaerobes:</u></p> <p><i>Clostridioides difficile</i></p>
<p><u>Gram-Negative Anaerobes:</u></p> <p><i>Bacteroides fragilis</i></p>
<p><u>Others:</u></p> <p><i>Chlamydia</i> species</p> <p><i>Mycoplasma</i> species</p> <p><i>Legionella</i> species</p>

## Pharmacokinetics

### Absorption

After oral administration *ZINNAT* is slowly absorbed from the gastrointestinal tract and rapidly hydrolysed in the intestinal mucosa and blood to release cefuroxime into the circulation.

Optimum absorption occurs when it is administered shortly after a meal.

Following administration of *ZINNAT* tablets peak serum levels (2.1 mg/l for a 125 mg dose, 4.1 mg/l for a 250 mg dose, 7.0 mg/l for a 500 mg dose and 13.6 mg/l for a 1 g dose) occur approximately 2 to 3 hours after dosing when taken after food.

### Distribution

Protein binding has been variously stated as 33 to 50% depending on the methodology used.

## **Metabolism**

Cefuroxime is not metabolised.

## ***Elimination***

The serum half life is between 1 and 1.5 hours.

Cefuroxime is excreted by glomerular filtration and tubular secretion. Concurrent administration of probenecid increases the area under the mean serum concentrations time curve by 50%.

## **Renal impairment:**

Cefuroxime pharmacokinetics have been investigated in patients with various degrees of renal impairment. Cefuroxime elimination half-life increases with decrease in renal function which serves as the basis for dosage adjustment recommendations in this group of patients (*See Dosage and Administration*). In patients undergoing haemodialysis, at least 60% of the total amount of cefuroxime present in the body at the start of dialysis will be removed during a 4-hour dialysis period. Therefore, an additional single dose of cefuroxime should be administered following the completion of haemodialysis.

## **Non-Clinical Information**

Animal toxicity studies indicated that cefuroxime axetil is of low toxicity with no significant findings.

## **PHARMACEUTICAL INFORMATION**

### **List of Excipients**

Microcrystalline cellulose.  
Croscarmellose sodium.  
Hypromellose  
Sodium lauryl sulphate.  
Hydrogenated vegetable oil.  
Silicon dioxide.  
Propylene glycol.  
Methylhydroxybenzoate (E218).  
Propylhydroxybenzoate (E216).  
Titanium dioxide (E171).  
Sodium benzoate (E211).

### **Shelf-Life**

The expiry date is indicated on the packaging.

## **Storage**

The storage conditions are detailed on the packaging.

*ZINNAT* tablets should be stored at temperatures not exceeding 30°C.

## **Nature and Contents of Container**

As registered locally.

## **Incompatibilities**

In the absence of compatibility studies cefuroxime axetil must not be mixed with other medicinal products..

## **Use and Handling**

None.

Not all presentations are available in every country.

***GSK is committed to the effective collection and management of human safety information relating to our products and we encourage healthcare professionals to report adverse events to us on +254 20 693 3200 or email us on [ke.safety@gsk.com](mailto:ke.safety@gsk.com)***

Full Prescribing Information is available on request from GlaxoSmithKline Pharmaceutical Kenya Limited, P.O. Box 78392-00507, 23 Likoni Road, Nairobi, Kenya.

Full Prescribing Information prepared in June 2021 based on VGDSv30 dated 09 October 2020.

***Trade marks are owned by or licensed to the GSK group of companies.***